UniProtKB/Swiss-Prot P00813: Variant p.Gly74Cys

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 74 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Glycine (G) to Cysteine (C) at position 74 (G74C, p.Gly74Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from glycine (G) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In ADASCID; delayed-onset. Any additional useful information about the variant.
Other resources: Links to websites of interest for the variant.

• Variant rs121908730 [ dbSNP | Ensembl ]

Sequence information

Variant position: 74 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 363 The length of the canonical sequence.
Location on the sequence: KPLTLPDFLAKFDYYMPAIA G CREAIKRIAYEFVEMKAKEG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 363	Adenosine deaminase
Site	58 – 58	Important for interaction with adenosine receptors and increasing their affinity for agonists
Site	62 – 62	Important for interaction with adenosine receptors and increasing their affinity for agonists
Modified residue	54 – 54	N6-acetyllysine
Mutagenesis	58 – 58	L -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; abolishes ADORA1 and ADORA2A modulator function.
Mutagenesis	60 – 60	D -> A. Moderately reduces enzyme activity; reduces ADORA1 and ADORA2A modulation.
Mutagenesis	61 – 61	F -> A. Decreases enzyme activity by reducing maximum velocity; reduces ADORA1 modulation.
Mutagenesis	62 – 62	L -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; abolishes ADORA1 and ADORA2A modulator function.
Mutagenesis	64 – 64	K -> A. Moderately reduces enzyme activity; no change in ADORA1 and ADORA2A modulation.
Mutagenesis	65 – 65	F -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; reduces ADORA1 and ADORA2A modulation.
Mutagenesis	66 – 66	D -> A. No change in enzyme activity; no change in ADORA1 and ADORA2A modulation.
Mutagenesis	69 – 69	M -> A. Decreases enzyme activity by reducing maximum velocity; reduces ADORA2A modulation.

Literature citations

Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del.
Arrendondo-Vega F.X.; Santisteban I.; Notarangelo L.D.; El Dahr J.; Buckley R.; Roifman C.; Conley M.E.; Hershfield M.S.;
Hum. Mutat. 11:482-482(1998)
Cited for: VARIANTS ADASCID CYS-74; MET-129; GLU-140; TRP-149 AND PRO-199;